This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Trisomy 21, mosaicism (mitotic nondisjunction)21삼염색체증, 섞임증형(유사분열비분리)

Contents and basic classification information
A. Classification codes ICD-10: Q90.1 / Special Copayment Reduction: V159 / Re-certification cycle: 5 years B. Synonyms None
C. Adult onset Delayed diagnosis in adulthood is common owing to phenotypic heterogeneity; Alzheimer's disease, premature aging, and immune abnormalities are the main complications in adulthood
1. History 2. Causes 3. Genetics 4. General epidemiology
5. Pathophysiology 6. Symptoms 7. Signs 8. Screening
9. Diagnosis 10. Treatment 11. Prognosis 12. Prevention
13. References

1. History

Trisomy 21 mosaicism began to be recognized through individual patient reports from the early 1960s, shortly after Lejeune first described standard trisomy in 1959. At that time cytogenetic techniques could analyze only a small number of metaphase cells, and the concept that different karyotypes coexist was technically and conceptually challenging. Clarke, Moore, and others reported in 1961 the first cases in which normal (46, XX or XY) cells and trisomic (47, +21) cells were mixed within the same individual.

In the 1960s–1970s, clinical observations accumulated that patients with mosaicism may have milder intellectual disability than patients with standard trisomy, or a phenotype that does not resemble Down syndrome. This suggested that the mosaic proportion and tissue distribution are key factors determining phenotypic severity. In the 1980s it was confirmed that the proportion of trisomic cells can differ among various tissues such as skin fibroblasts, buccal mucosa cells, and blood cells.

With the introduction of FISH in the 1990s, karyotype analysis at the single-cell level became possible, and analyzing more cells made it possible to detect low-level mosaicism. Since the 2000s, SNP microarray and next-generation sequencing have provided tools to evaluate the mosaic proportion quantitatively. At present, the phenotypic heterogeneity of mosaic Down syndrome, variation in cognitive function, and the false-negative problem of prenatal NIPT are active research topics. Cases of mosaic Down syndrome being misdiagnosed as normal or diagnosed late in adulthood continue to be reported, so raising clinical awareness is an important task.

Recently, under the concept of induced mosaicism, the phenomenon of trisomy rescue, in which an early trisomic zygote "rescues" some of its trisomic cells during embryonic development to produce euploid cells, has also come to be recognized as an important mechanism of mosaicism.


2. Causes

Trisomy 21 mosaicism (Q90.1) arises from mitotic nondisjunction or trisomy rescue. Both mechanisms are errors in cell division that occur in early embryonic development after fertilization, with the result that euploid (46 chromosomes) cells and trisomy 21 (47 chromosomes) cells coexist within one individual.

Mitotic nondisjunction

Owing to an error in which the sister chromatids of chromosome 21 fail to separate normally during early cell division of a euploid zygote (46,XX or 46,XY), some daughter cells acquire trisomy (47,+21). The earlier the cell division at which this error occurs—that is, the fewer the number of embryonic cells—the higher the proportion of trisomic cells. Conversely, an error in later embryonic stages affects only a small number of cells and produces a low proportion of mosaicism. Therefore, the mosaic proportion can be regarded as an inverse function of the timing of the error.

Trisomy rescue

This is the phenomenon in which an embryo that was trisomy 21 (47,+21) from fertilization owing to meiotic nondisjunction loses one of the three chromosomes 21 during early mitosis (anaphase lag), restoring euploidy in some daughter cells. In this case the remaining cell lineage becomes euploid (46,XX/XY), and trisomic cells also remain, forming mosaicism. In euploid cells after trisomy rescue, uniparental disomy (UPD) may occur, and UPD of chromosome 21 may have an additional effect on the phenotype.

Cell selection

During embryonic development, cellular selection pressure can affect the mosaic proportion. Trisomic cells may have a proliferative disadvantage compared with euploid cells, so a tendency for the proportion of trisomic cells to decrease as development proceeds is also observed in some cases. Conversely, it has been proposed that trisomic cells may have a proliferative advantage in specific tissues (e.g., brain neural progenitor cells).


3. Genetics

The karyotype of mosaic Down syndrome is written as 47,XX,+21[n]/46,XX[m] or 47,XY,+21[n]/46,XY[m], where n and m indicate the numbers of trisomic cells and euploid cells, respectively. The mosaic proportion can differ markedly depending on the tissue and cell type analyzed, and this is the key cause of phenotypic heterogeneity.

Tissue-specific mosaic proportion

The proportion of trisomy measured in peripheral blood lymphocytes may differ from the proportions in other tissues such as skin fibroblasts, buccal mucosa cells, and germ cells. In particular, the proportion of trisomy in brain neurons is presumed to have the most direct effect on clinical cognitive function, but direct analysis of brain tissue is not practically possible. Therefore, the mosaic proportion on peripheral blood karyotype does not completely predict phenotypic severity.

Risk of uniparental disomy (UPD)

In mosaicism arising by the trisomy rescue mechanism, the euploid cell lineage may have UPD. Chromosome 21 has no known imprinted genes associated with UPD itself, so the phenotypic effect of UPD alone is limited, but if a recessive mutation is present on both alleles of the same parental origin, there is a risk that a homozygous phenotype will appear.

Recurrence risk

For mosaic Down syndrome due to mitotic nondisjunction, the parental karyotypes are normal, so the recurrence risk is low, similar to standard trisomy. However, if gonadal mosaicism is present at the parental germ cell level, the risk of transmission to children may increase, and this is difficult to confirm clinically.

Genetic basis of phenotypic heterogeneity

The higher the mosaic proportion (proportion of trisomic cells 70% or more), the more the phenotype resembles standard trisomy, and the lower the proportion (below 10%), the milder the phenotype or the absence of the typical features of Down syndrome, so that it may be overlooked as normal. However, the correlation between the mosaic proportion and phenotypic severity is imperfect, and phenotypes can differ greatly even with the same mosaic proportion. This reflects differences according to which developmental lineages the trisomic cells are mainly distributed in, that is, the tissue distribution pattern.


4. General epidemiology

Mosaic Down syndrome (Q90.1) accounts for about 1–2% of all Down syndrome. The birth frequency is estimated at about 1/50,000–1/70,000 of all births, but because diagnosis is missed in cases of mild phenotype, the actual prevalence may be higher. Missed diagnosis occurs especially in patients with a low mosaic proportion, and some are first diagnosed in adulthood after childhood.

Effect of maternal age

In mosaicism arising by the trisomy rescue mechanism, the primary event is meiotic nondisjunction, so the maternal age effect partly applies. In contrast, in the pure mitotic nondisjunction mechanism, it is an error of early embryonic cell division and can occur regardless of maternal age. There are reports that the maternal age distribution in patients with mosaicism tends to be somewhat younger than in patients with standard trisomy, but results are inconsistent among studies.

Diagnostic delay and clinical implications

Patients with mosaic Down syndrome lack the typical Down syndrome phenotype or have it only mildly, so developmental delay in childhood may not be prominent. For this reason, it is not uncommon for an adult who was thought to have normal intelligence to be first diagnosed with mosaic Down syndrome on chromosome testing. If diagnosis is delayed, opportunities to monitor complications such as hypothyroidism, hearing loss, atlantoaxial instability, and congenital heart disease may be missed.

False negatives in prenatal screening

NIPT analyzes the proportion of chromosome 21 in cell-free fetal DNA in maternal blood, and in mosaicism, if the proportion of trisomic cells is low, the increase in the proportion of chromosome 21 in total fetal DNA is slight, so a false negative may occur. Differentiation from confined placental mosaicism is also a problem. Therefore, when there is clinical suspicion, Down syndrome should not be excluded on the basis of a negative NIPT result alone.


5. Pathophysiology

Mosaic Down syndrome arises from a mitotic error or a trisomy rescue event occurring in the early developmental stage of the zygote, that is, when the number of embryonic cells is from several to several tens. The fidelity of cell division at this stage is known to be lower than in later somatic cell division.

Cell biology of mitotic nondisjunction

In mitosis, sister chromatids are held together by the cohesin complex until metaphase and separate in anaphase when cohesin is cleaved by activation of separase. The spindle assembly checkpoint (SAC) machinery—BubR1, Mad2, Bub1, etc.—monitors whether each kinetochore is correctly attached to spindle microtubules from opposite directions. If the SAC machinery is incomplete in early embryonic cells or microtubule-kinetochore attachment is unstable, nondisjunction of chromosome 21 sister chromatids occurs. As a result, 47,+21 daughter cells and 45,-21 daughter cells are produced; the 45,-21 cells mostly undergo cell death and are lost, and mosaicism of 47,+21 cells and 46 cells is formed.

Trisomy rescue and uniparental disomy

When a 47,+21 zygote formed by meiotic nondisjunction loses one of the three chromosomes 21 by anaphase lag during early embryonic division, the daughter cells regain euploidy of 46,XX or 46,XY. Because the chromosome 21 that is lost is determined at random, uniparental disomy (UPD), in which the remaining two chromosomes 21 are of the same parental origin (maternal or paternal), can occur with a 1/3 probability in some cases. The clinical effect of chromosome 21 UPD itself is not large, but genetic counseling that takes this mechanism into account is needed.

Determinants of the mosaic proportion

The earlier the cell division stage at which the nondisjunction error occurs (2-cell to 8-cell stage), the higher the proportion of trisomic cells, and the later (64 cells or more), the lower the proportion. In addition, in tissues with a rapid rate of cell division, the proportion of trisomic cells may change over time, and in tissues where euploid cells have a proliferative advantage, the trisomic proportion may decrease.

Tissue-specific developmental effects of trisomy 21

In brain development, the proportion of trisomic cells at the neural progenitor cell stage affects the final number of neurons and cortical composition. Even when the mosaic proportion is low, if trisomic cells are concentrated in a specific brain region during the developmental window sensitive to neurodevelopment, the phenotype may be more severe than expected. Conversely, even if the peripheral blood trisomy proportion is high, cognitive function may be only mildly affected if the proportion in brain neurons is low.


6. Symptoms

The clinical symptoms of mosaic Down syndrome appear in the same systems as standard trisomy (Q90.0), but are often expressed in a generally milder or incomplete form. However, the phenotypic range is wide, and some patients show a typical Down syndrome phenotype so pronounced that it is difficult to distinguish from standard trisomy.

Intellectual function and development

In mosaic Down syndrome, IQ averages 50–70 (mild intellectual disability), but some patients have borderline intelligence with an IQ of 70–85 or fall within the normal range. Developmental delay is mild, so no particular findings may be observed until school age without early intervention. Language developmental delay, learning difficulty, and attention problems are the main symptoms in childhood, but because these are nonspecific, they may be classified as simple developmental delay or learning disability rather than Down syndrome.

Heterogeneity of the physical phenotype

The typical facial features of Down syndrome (upslanting palpebral fissures, epicanthal folds, Brushfield spots, flat nose, short neck, small ears) may be weak or only partly observed. Hypotonia may also be mild, so feeding difficulty in the neonatal period may not be prominent. Findings such as a single palmar crease, clinodactyly of the little finger, and a widened toe gap may also appear incompletely.

Congenital heart disease

Congenital heart disease also occurs in mosaic Down syndrome, with an incidence reported at about 20–30%, somewhat lower than in standard trisomy (about 40–50%). Atrioventricular septal defect (AVSD), ventricular septal defect (VSD), etc. may occur, and echocardiography must be performed after the diagnosis is confirmed.

Immune and hematologic

A tendency toward recurrent infections, autoimmune diseases (thyroiditis, celiac disease, alopecia), and increased risk of leukemia are also observed in mosaic Down syndrome. However, the incidence tends to be somewhat lower or the clinical symptoms milder than in standard trisomy.

Endocrine and thyroid abnormalities

The risk of hypothyroidism (congenital or acquired autoimmune thyroiditis) is also increased in mosaic Down syndrome. Regular thyroid function tests are essential. The risk of diabetes is also higher than in the general population.


7. Signs

The signs seen in patients with mosaic Down syndrome belong to the same systems as those of standard trisomy but are often expressed in a mild and incomplete form. The absence of typical signs is the main cause of delayed diagnosis.

Mildness of facial signs

Upslanting palpebral fissures may not be evident, and epicanthal folds may be weak or absent. A flat nasal bridge and small ears with abnormal position may also be subtle. Therefore, even experienced clinicians sometimes fail to recognize the facial phenotype of mosaic Down syndrome as Down syndrome on first seeing it.

Neurodevelopmental signs

Delay in developmental milestones may be mild, or the timing of achieving milestones may be at the lower limit of the normal range. Hypotonia may also be mild, so referral to physical therapy may not be made. Learning difficulty at school, attention problems, and delayed expressive language may be the first clinical clues.

Skeletal and joint signs

Atlantoaxial instability (AAI) can occur in mosaic Down syndrome as well, and evaluation before high-risk activities is recommended. Flat feet, joint hyperextension, and ligamentous laxity may also be observed.

Skin and limb signs

A single palmar crease, clinodactyly of the little finger, and a widened toe gap may appear unilaterally or incompletely. It is difficult to diagnose Down syndrome from skin signs alone, and they must be evaluated in combination with other signs.

Prenatal ultrasound findings

Fetuses with mosaic Down syndrome may have weak or absent Down syndrome ultrasound markers, such as increased nuchal translucency (NT), absent nasal bone, and duodenal atresia, compared with fetuses with standard trisomy, so there is a risk of being read as normal on prenatal ultrasound screening.


8. Screening

In the diagnosis of mosaic Down syndrome, it is important in clinical practice to clearly understand the limitations of screening tests. Screening tools optimized for standard trisomy have low sensitivity for mosaicism, and the risk of false negatives is ever present.

Limitations of NIPT

NIPT analyzes the proportion of chromosome 21 in cell-free fetal DNA (cffDNA) in maternal blood. In fetuses with mosaicism, the increase in the proportion of chromosome 21 in the total cffDNA pool is diluted in proportion to the proportion of trisomic cells, so in mosaicism with a low trisomic proportion the NIPT result may be negative (within the normal range). In addition, the proportion of trisomy in the placenta may differ from that in fetal body tissues (confined placental mosaicism), complicating interpretation. When there is clinical suspicion, invasive confirmatory testing should be considered despite a negative NIPT result.

First-trimester combined screening

Nuchal translucency (NT) in fetuses with mosaicism may be only mildly increased or within the normal range, so the combined screening risk may be calculated as low. Serum markers (PAPP-A, free β-hCG) in mosaicism may also differ from the standard trisomy pattern.

Neonatal and pediatric clinical screening

When Down syndrome is not clinically suspected because typical signs are absent in the neonatal period, the diagnosis of Down syndrome may be made incidentally at a pediatric developmental assessment or at chromosome testing in adulthood. It is important to include mosaic Down syndrome in the differential diagnosis of patients with developmental delay, learning disability, recurrent infections, or mild facial phenotypic abnormalities.

Pediatric and adult monitoring

After confirmation, regular monitoring of thyroid function, hearing, vision, cardiac function, atlantoaxial stability, etc. is performed in the same way as for standard trisomy. From adulthood onward, cognitive function assessment for Alzheimer's disease screening should be included.


9. Diagnosis

Confirmation of mosaic Down syndrome is by cytogenetic testing, and analysis of more cells is required than for standard trisomy.

G-banding karyotype analysis and cell number

Routine karyotype analysis analyzes 20 metaphase cells, but when mosaicism is suspected, at least 30–50 or more cells should be analyzed so that a low proportion of trisomic cells can be detected. The fewer the cells analyzed, the higher the risk of missing low-level mosaicism. For example, analyzing 20 cells makes it statistically difficult to detect a mosaic proportion of about 10% or less.

Interphase FISH

The number of chromosome 21 signals can be counted in a large number of cells (several hundred), making it more sensitive than karyotype analysis for detecting low-level mosaicism. In particular, FISH on peripheral blood interphase nuclei can produce results quickly and is useful for quantifying the proportion.

SNP microarray and CMA

SNP array can quantitatively estimate the proportion of trisomic cells through the B-allele frequency (BAF) pattern, and can theoretically detect mosaicism of about 5–10% or more. It is also useful for confirming uniparental disomy (UPD).

Mosaicism detection based on next-generation sequencing (NGS)

Mosaicism at even lower proportions (below 5%) can be detected by low-pass whole-genome sequencing (low-pass WGS) or high-depth analysis of specific chromosomes. For research purposes, a method of directly analyzing the karyotype of each cell by single-cell sequencing is also applied.

Need for multi-tissue analysis

When there is clinical suspicion but mosaicism is not confirmed on peripheral blood karyotype analysis, additional cytogenetic analysis of other tissues such as skin fibroblasts (skin biopsy), buccal mucosa cells, and urinary epithelial cells is recommended. Because the trisomy proportion differs among tissues, it is difficult to exclude mosaicism on the basis of the analysis result of a single tissue.


10. Treatment

The treatment principles for mosaic Down syndrome are the same as for standard trisomy, with individualized multidisciplinary management according to accompanying complications and the individual's functional level.

Correction of congenital malformations

When congenital heart disease is identified, surgical correction is performed on the same principles as for standard trisomy. Gastrointestinal malformations are likewise treated according to surgical indications. A low mosaic proportion does not necessarily mean a low severity of cardiac malformation, so echocardiography must be performed after mosaicism is confirmed.

Developmental rehabilitation and education

The intensity of early intervention (speech therapy, occupational therapy, physical therapy) is adjusted according to the level of intellectual function. Patients with mild intellectual disability receive support in an inclusive education setting, and patients with borderline intelligence combine general education with special support. Because the range of developmental potential is greater than in standard trisomy, care is taken not to set low expectations for patients with mosaicism.

Thyroid and endocrine management

Hypothyroidism is treated with levothyroxine, maintaining the target TSH range. Regular thyroid function tests, obesity prevention, and metabolic monitoring are performed.

Mental health and behavioral support

When anxiety, obsessive-compulsive disorder, depression, or autism spectrum disorder accompany, appropriate psychiatric evaluation and treatment are needed. Patients with mosaicism may have a greater ability to be aware of their own condition than those with standard trisomy, so identity, social integration, and psychological support become important issues.

Adult management

According to adult Down syndrome management guidelines, baseline assessment of cognitive function for Alzheimer's disease screening (from age 30–35) and regular follow-up are recommended. Employment support, community living, and training in independent living skills are also key elements of adult management.


11. Prognosis

The prognosis of mosaic Down syndrome is generally better than that of standard trisomy, but individual differences are very large depending on the proportion and tissue distribution of trisomic cells and accompanying complications.

Cognitive prognosis

Patients with mild intellectual disability or borderline intelligence can live semi-independently, and some succeed in competitive employment. However, patients with severe intellectual disability need support similar to that for standard trisomy. Early intervention and appropriate educational support have an important effect on the cognitive prognosis.

Life expectancy

Because the incidence of congenital heart disease and complications may be lower than in standard trisomy, overall life expectancy is estimated to be longer. However, the risk of Alzheimer's disease is increased as long as chromosome 21 trisomic cells are present in the brain, so monitoring of cognitive decline in adulthood is needed even when the mosaic proportion is low.

Social integration and quality of life

Patients with mosaic Down syndrome with a mild phenotype can achieve a high level of social integration. Quality of life improves greatly when appropriate support and opportunities are provided, and a person-centred plan is important.


12. Prevention

Prevention of mosaic Down syndrome is similar to the prenatal screening strategy for standard trisomy, but it is important to recognize the limitations of screening tests and to actively perform confirmatory testing when clinically suspected.

Recognizing the limitations of prenatal screening and confirmation

Even if NIPT is negative, if there are findings clinically suspicious for Down syndrome (abnormal ultrasound markers or serum markers), invasive confirmatory testing is recommended. At prenatal confirmation, the laboratory is asked to analyze a sufficient number of cells (50 or more) on karyotype analysis.

Preventing missed diagnosis

When clinical findings such as developmental delay in childhood, a mild Down syndrome phenotype, or recurrent infections are present, exclusion of mosaicism through cytogenetic testing is actively pursued. Additional tissue testing such as skin fibroblasts is also used as needed.

Prevention and early detection of complications

After confirmation, in accordance with standard Down syndrome management guidelines, echocardiography, thyroid function tests, hearing tests, ophthalmologic examination, and evaluation of atlantoaxial instability are performed regularly to detect and treat complications early. Continued follow-up is needed in adulthood as well.

Family genetic counseling

Through genetic counseling for the parents of a child with mosaic Down syndrome, information is provided on recurrence risk and future pregnancy planning. It is explained that even when parental karyotype testing shows no abnormality, the possibility of germ cell mosaicism cannot be excluded.


13. References

  1. Hultén MA, Patel S, Jonasson J, Iwarsson E. On the origin of the maternal age effect in trisomy 21 Down syndrome: the Oocyte Mosaicism Selection model. Reproduction. 2010;139(1):1–9. doi:10.1530/REP-09-0088
  2. Papavassiliou P, York TP, Gursoy N, et al. The phenotype of persons having mosaicism for trisomy 21/Down syndrome reflects the percentage of trisomic cells present in different tissues. Am J Med Genet A. 2009;149A(4):573–583. doi:10.1002/ajmg.a.32729
  3. Dunn TM, Demers LM, Cohn D. The effect of trisomy 21 mosaicism on clinical phenotype. Genet Med. 2018;20(4):472–478.
  4. Embleton ND, Wyllie JP, Wright MJ, et al. Natural history of trisomy 21 in the perinatal period. Arch Dis Child Fetal Neonatal Ed. 1996;75(3):F172–F175. doi:10.1136/fn.75.3.F172
  5. Bull MJ; Committee on Genetics. Health supervision for children with Down syndrome. Pediatrics. 2011;128(2):393–406. doi:10.1542/peds.2011-1605
  6. Benn PA. Uniparental disomy: a review of causes and clinical significance. Clin Genet. 1998;54(4):271–285. doi:10.1034/j.1399-0004.1998.5440401.x
  7. Molina O, Blanco J, Vidal F. Meiotic behavior of sex chromosomes in normal XY males and in carriers of sex chromosome anomalies. Cytogenet Genome Res. 2010;128(1–3):69–80.
  8. Shinawi M, Cheung SW. The array CGH and its clinical applications. Drug Discov Today. 2008;13(17–18):760–770. doi:10.1016/j.drudis.2008.06.007
  9. Hassold T, Hall H, Hunt P. The origin of human aneuploidy: where we have been, where we are going. Hum Mol Genet. 2007;16(R2):R203–R208. doi:10.1093/hmg/ddm243
  10. Wiseman FK, Alford KA, Tybulewicz VL, Fisher EM. Down syndrome—recent progress and future prospects. Hum Mol Genet. 2009;18(R1):R75–R83. doi:10.1093/hmg/ddp010